Elicio Therapeutics

ELI-002 was shown to be well-tolerated with no dose limiting toxicity or cytokine release syndromeA high proportion of patients had tumor biomarker reduction (77%) with 32% having complete clearanceRobust mKRAS-specific T cell responses…

Shares of Elicio to commence trading on Nasdaq under the ticker symbol “ELTX” on June 2, 2023First in human Phase 1 data on lead candidate ELI-002 to be presented at 2023 American Society of Clinical Oncology (ASCO) BOSTON, June 01,…

AMP-CpG efficiently targets the lymph nodes to promote potent and comprehensive innate immune activation resulting in enhanced T and B cell responses with improved functionality and persistence Application of AMP-CpG enables potent…

ELI-005, containing the Amphiphile vaccine adjuvant AMP-CpG, induced >25-fold higher antigen-specific T cells in the peripheral blood and exhibited potent killing of antigen-positive targets in vivo that were maintained for >5 months…

Data showed AMP combination with TCR-T cell therapy promotes durable responses against aggressive solid tumors in a mouse model where TCR-T cells alone have no effectAMP combination with TCR-T cell therapy induces marked T cell expansion,…